Assignee
BELLICUM PHARMACEUTICALS INC
US·9 granted patents·18 pending applications·85 citations·filing 2013–2021
Top patents by PatentIndex Score
27 records- 0194US9434935B2Modified caspase polypeptides and uses thereofBELLICUM PHARMACEUTICALS INC·Filed 2013·Granted Sep 6, 2016·31 cites·9 claims
- 0293US10888608B2Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2015·Granted Jan 12, 2021·8 cites·16 claims
- 0390US9913882B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2014·Granted Mar 13, 2018·16 cites·57 claims
- 0489US9944690B2Methods for controlling T cell proliferationBELLICUM PHARMACEUTICALS INC·Filed 2014·Granted Apr 17, 2018·14 cites·15 claims
- 0587US9932572B2Modified Caspase polypeptides and uses thereofBELLICUM PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·6 cites·13 claims
- 0685US10525110B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2018·Granted Jan 7, 2020·4 cites·33 claims
- 0783US10918705B2Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Granted Feb 16, 2021·1 cites·22 claims
- 0880US10934346B2Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12BELLICUM PHARMACEUTICALS INC·Filed 2015·Granted Mar 2, 2021·5 cites·15 claims
- 0967US11839647B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Granted Dec 12, 2023·0 cites·25 claims
- 1065US2021346477A1Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1161US2013323834A1Methods for inducing selective apoptosisBELLICUM PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1260US2022062338A1Psca car-t cellsBELLICUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1357US2022125837A1Methods for controlled elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1456US2014023647A1Method for treating solid tumorsBELLICUM PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1556US2022152100A1Methods for controlled activation or elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1655US2023065562A1Dual controls for therapeutic cell activation or eliminationBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1755US2018251746A1Modified caspase polypeptides and uses thereofBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1853US2022273717A1Improved formulations for immune cellsBELLICUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1950US2020347148A1Methods for enhancing and maintaining car-t cell efficacyBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2049US2018265566A1Methods for controlling t cell proliferationBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2148US2022002674A1T cells with suicide switchBELLICUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2244US2021147507A1Methods to augment or alter signal transductionBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2341US2017166877A1Dual controls for therapeutic cell activation or eliminationBELLICUM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2437US2016166613A1Methods for controlled elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2536US2020308144A1Multimeric piperidine derivativesBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2635US2016175359A1Methods for controlled activation or elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2733US2015328292A1Caspase polypeptides having modified activity and uses thereofBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →